Literature DB >> 24846315

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

T Kawada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24846315     DOI： 10.1007/s00198-014-2721-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  4 in total

1.  Sample size estimation for GEE method for comparing slopes in repeated measurements data.

Authors:  Sin-Ho Jung; Chul Ahn
Journal:  Stat Med       Date:  2003-04-30       Impact factor: 2.373

2.  Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.

Authors:  Toshitaka Nakamura; Toshitsugu Sugimoto; Tetsuo Nakano; Hideaki Kishimoto; Masako Ito; Masao Fukunaga; Hiroshi Hagino; Teruki Sone; Hideki Yoshikawa; Yoshiki Nishizawa; Takuo Fujita; Masataka Shiraki
Journal:  J Clin Endocrinol Metab       Date:  2012-06-20       Impact factor: 5.958

3.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

4.  Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

Authors:  T Sugimoto; T Nakamura; Y Nakamura; Y Isogai; M Shiraki
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507
  4 in total
  2 in total

Review 1.  Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures.

Authors:  Byung-Woo Min; Kwang-Soon Song; Ki-Cheor Bae; Chul-Hyun Cho; Eun-Suck Son; Kyung-Jae Lee
Journal:  Hip Pelvis       Date:  2015-03-31

2.  Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada.

Authors:  T Sugimoto; T Nakamura; Y Nakamura; Y Isogai; M Shiraki
Journal:  Osteoporos Int       Date:  2014-05-08       Impact factor: 4.507
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.